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Abstract
Background: Epidemiologic data of Herpes Zoster (HZ) disease in Spain are scarce. The objective of this study was
to assess the epidemiology of HZ in the Valencian Community (Spain), using outpatient and hospital electronic
health databases.
Methods: Data from 2007 to 2010 was collected from computerized health databases of a population of around 5
million inhabitants. Diagnoses were recorded by physicians using the International Classification of Diseases, 9th
Revision, Clinical Modification (ICD-9-CM). A sample of medical records under different criteria was reviewed by a
general practitioner, to assess the reliability of codification.
Results: The average annual incidence of HZ was 4.60 per 1000 persons-year (PY) for all ages (95% CI: 4.57-4.63),
is more frequent in women [5.32/1000PY (95% CI: 5.28-5.37)] and is strongly age-related, with a peak incidence at
70-79 years. A total of 7.16/1000 cases of HZ required hospitalization.
Conclusions: Electronic health database used in the Valencian Community is a reliable electronic surveillance tool
for HZ disease and will be useful to define trends in disease burden before and after HZ vaccine introduction.
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Background
Herpes Zoster (HZ; shingles) results from the reactiva-
tion of Varicella-Zoster Virus (VZV) that has been latent
in the spinal and cranial sensory ganglia after primary
infection with varicella (chickenpox), usually during
childhood [1]. A vesicular skin rash in the affected
dermatome, commonly accompanied by acute pain,
characterizes the acute phase of HZ disease.
Approximately 14% of all patients with shingles will
develop complications [2]. The most common and
weakening is postherpetic neuralgia (PHN), defined by
most investigators as pain being present at 90 days after
the rash appears [1,2]. Both the acute pain associated
with HZ and PHN have a negative impact on health-
related quality of life, interfering significantly with
physical, emotional, and social functioning [3-6], and
quantitatively similar to congestive heart failure, severe
depression, acute myocardial infarction, or uncontrolled
diabetes [7].
The risk of HZ and its complications increases with
advancing age, being more manifest in persons over
50-60 years of age [1,2,8,9]. Among individuals who
reach age 85 years of age, approximately 50% will have
experienced at least one episode of HZ [10]. The inci-
dence of acute HZ in the European general population
ranges between 2.0-4.8 per 1000 persons-year (PY) for
all ages, and increases after age 50 years to around 7-8/
1000 PY [11,12]. Over the coming decades, Europe’s
demographic patterns will change dramatically, and it is
expected that our populations will become older than
ever before [13]. This suggests that the incidence of HZ
could vary in relation to an older population, possibly as
a result of immunosenescence [14].
Several studies support the hypothesis that exposure
to childhood varicella reduces the risk of developing HZ
by boosting specific immunity to VZV [15-19]. Based on
this hypothesis, mathematical models suggest that a suc-
cessful childhood vaccination program may decrease the
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circulation of wild-type VZV, and therefore the stimula-
tion of cellular immunity that could prevent the occur-
rence of shingles in the adult population [20-23]. This
could have significant public health consequences, if a
universal mass VZV vaccination program is imple-
mented in childhood. Although this issue is still contro-
versial and there is no firm evidence that this increase
will occur [24-26], monitoring of disease trends over
time will help understand the impact of different factors
upon the incidence of HZ. In the Valencian Community
(Spain), varicella vaccination is recommended and
funded at 12 years of age in those subjects who have not
been in clear contact with the virus. This helps avoid se-
vere cases in adults with no impact upon circulation of
the virus. About 30% of toddlers also receive the vaccine
after their pediatrician’s recommendation [27]. With this
low coverage figure, the virus is circulating within the
population and no effect upon HZ is expected.
The efficacy of a live attenuated zoster vaccine,
Zostavax®, in preventing HZ and PHN has been tested in
adults ≥ 60 years of age, yielding efficacy rates of 51%
and 67%, respectively [28], and of 70% for incident HZ
in subjects aged 50–59 years old [29]. In a recent
population-based study of 766,330 individuals aged ≥ 65
years, the effectiveness was seen to be 48% [30]. This
vaccine is generally well tolerated, has been licensed in
the European Union in 2006 for people aged ≥50 years
[31], and is expected to be widely used in Spain over the
next few years. Another adjuvanted vaccine is under de-
velopment [32-34].
In Spain, HZ is presently not a notifiable disease, and
epidemiological data are scarce. A recent prospective
study in the Valencian Community (Spain) showed an
HZ incidence of 4.1 per 1000 persons > 14 years of age
during 2007 [35,36]. Reliable epidemiological data are
needed before any universal recommendation of HZ vac-
cines can be made, in order to assess the impact of HZ
vaccination. The purpose of this study was to explore
the epidemiology of HZ in the Valencian Community
during a four-year period (January 2007 to December
2010), and to estimate the reliability of the regional elec-
tronic medical database for epidemiological studies, with
a view to creating surveillance tools for future and
efficient assessments of HZ incidence in the post-HZ
vaccine era.
Methods
Setting and study population
The Valencian Community, in the east of Spain, has a
population of 5,117,190 inhabitants (2011) [37], and over
98% are covered by the national public health system
(NHS) [38]. Primary care visits and hospitalizations are
recorded in clinical databases. Using these, we sought
cases of HZ of all ages and both sexes attended in the
NHS from 1 January 2007 to 20 December 2010. From
each HZ case we obtained all medical visits, prescrip-
tions and demographic data.
Abucasis electronic healthcare database
The Abucasis electronic medical database was imple-
mented in the Valencian Community for outpatient and
primary care settings in 2006, and offers the possibility
of linking patient care and public health [39]. From 2006
to 2010 (when the whole health system was computer-
ized), the percentage of the population included in
Abucasis increased from 73.1% in 2007 to 88.8% in 2008
and 95.7% in 2009 (Abucasis managers, personal com-
munication). Abucasis contains an ambulatory informa-
tion system called SIA, which registers any medical
contact (visit), and the attending physician uses a drop-
down menu with the International Classification of
Diseases, 9th Revision, Clinical Modification (ICD-
9-CM) to record diagnoses. Abucasis also links other da-
tabases: Care Provision Management (GAIA), which is
the drug information system available to the different
professionals involved in prescription and dispensation,
addressed from the Department of Health; and the Vac-
cine Information System (RVN) [40]. Other databases
used in this study, such as the Hospital Data Surveil-
lance System (CMBD), are described elsewhere [41] and
can be linked through a unique personal identification
number (SIP), for the collection of demographic data.
Case definition
For the identification of incident cases of HZ, we
searched SIA for any subject with first appearance of an
HZ-related ICD-9-CM code (all ICD-9-CM 053 codes:
HZ or HZ related complications), and the CMBD data-
base for an HZ diagnosis in any position (1st to 9th).
GAIA was searched for information on all subjects who
were prescribed antiviral drugs (acyclovir, famcyclovir or
valacyclovir) at doses only licensed for use in HZ by the
Spanish Medicines Agency (AEMPS).
Any outpatient medical contact or visit, hospital ad-
mission or electronic prescription related to HZ was
considered as a medical encounter. In order to avoid an
overestimation of results, and in an attempt to identify
recurrent HZ episodes, each medical encounter not pre-
ceded by another encounter in the last six months, and
succeeded by another encounter in the following three
months was considered as a recurrent HZ case.
To assess data quality, a total of 550 medical records
were reviewed by a physician (NMT) in order to assess
coding reliability and the accuracy of the filters used.
These medical records were randomly selected after re-
quest of the following criteria: definition of incident HZ
case and recurrent HZ case (300 records reviewed), pre-
scription of specific topical and oral HZ antiviral drugs
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without a specific HZ ICD-9-CM code (100 records
reviewed), discordance of the narrative diagnostic de-
scription with the assigned ICD-9-CM HZ code (100 re-
cords reviewed), and hospitalizations with an HZ
diagnosis not appearing in the Abucasis database (50 re-
cords reviewed). In order to determine recurrence, each
medical contact in the Abucasis database from 1 June
2006 to 31 March 2011 was evaluated. Confirmation of
an HZ diagnosis required an HZ ICD-9-CM code in
addition to application of at least one of the following
criteria:
1. Detailed physician description of characteristic HZ
skin lesions
2. Prescription of antiviral drugs
3. Temporary disability under HZ diagnosis
4. Referral for specialist assessment due to HZ disease,
without a subsequent diagnostic exclusion of HZ
diagnosis
Our data from 2007 were graphed together with the
results obtained in a regional prospective cohort study
in patients aged > 14 years and carried out in 25 primary
care settings in the Valencian Community during the
same year [35,36].
All databases were merged using the database manager
MySQL 5.1. The random selection for quality control of
coding was performed using its “rand” function. Ana-
lyses were performed using MySQL and Epidat 3.1. We
calculated annual incidence rates of HZ by dividing the
number of cases by the persons registered in SIP in each
year. The exact 95% confidence interval (CI) for the inci-
dence rates was calculated on the basis of a normal
distribution. The Risk Ratio was calculated to assess dif-
ferences between males and females.
Ethical considerations
The study protocol abided with the principles of the
Declaration of Helsinki and was approved by the Public
Health Ethics Committee of Valencia. Waiver of in-
formed consent was accepted for medical history review.
Results
HZ case confirmation
We identified a total of 85,586 persons in SIA and/or
CMBD with a first diagnosis of HZ. Our criteria of re-
currence were met by 3300 of them. After chart review,
the positive predictive value (PPV) for HZ case defin-
ition was 92.7% (95% CI 89.1-95.4), and for recurrent
HZ cases was 55.1% (95% CI 47.0-63.0). Due to the low
PPV of the recurrence filter, only the incident HZ cases
were included in our estimations.
The PPV for HZ diagnosed only by high-dose antiviral
prescription was 26% (95% CI: 17.7-35.7), therefore, no
case identified only by the prescription of antivirals was
considered as an HZ case.
Epidemiological analysis
HZ incidence
Over the four-year study period, we identified 85,586
persons with incident cases of HZ requiring medical
care, which correspond to an incidence in all age groups
of 4.60/1000 PY (95% CI: 4.57-4.63). The figures remai-
ned rather constant over the years: 4.58/1000 PY
(95% CI: 4.51-4.65) in 2007, 4.89 (95% CI: 4.83-4.95)
in 2008, 4.67 (95% CI: 4.61-4.73) in 2009, and 4.29
(95% CI: 4.24-4.35) in 2010 (Figure 1).
HZ incidence rates were strongly aged-related, and
more than half of the cases involved patients over 50
years of age (63.18%) (Table 1). The incidence in the
non-pediatric age group (≥ 15 years) was 5.02/1000 PY
(95% CI: 4.99-5.06), while in the target population for
HZ vaccine (adults aged ≥50 years) the incidence was
8.60/1000 PY (95% CI: 8.53-8.67). This trend was
maintained each year during the whole study period. An
incidence peak was observed in those aged 70-79 years,
with a maximum of 11.55/1000 PY (95% CI: 11.32-
11.79) in women and 9.41/1000 PY (95% CI: 9.18-9.65)
in men. A drop in incidence in the older age group oc-
curred in the primary care database but was not seen in
the hospitalizations (Table 2).
HZ was less common among men [3.86/1000 PY
(95% CI: 3.82-3.90)] than women [5.32/1000PY (95%
CI: 5.28-5.37)] in the total population, with a RR 0.73
(95 CI: 0.72-0.74) (Table 1).
A total of 1458 hospitalizations with HZ related ICD-
9-CM codes occurred during the study period (an an-
nual average of 365 admissions). Of these, 683 were men
(46.8%) and 775 women (53.2%). The mean age was 67.5
years (range 0-100). Characteristics referred to hospital-
ized population and hospitalization rates are shown in
Tables 2 and 3.
HZ was the first coded diagnosis in 383 cases (26.2%
of all hospitalizations). For these cases, secondary codes
were hypertension (7.8%), hematopoietic malignancies
(3.4%), HIV infection (2.6%), diabetes mellitus (2.3%)
and urinary tract infection (1.3%). In 5.7% of the cases,
HZ was the only diagnostic code. HZ was the second
listed diagnosis in 250 admissions (17.1%). For these
cases, first coded diagnoses were respiratory tract infec-
tious diseases (8%), meningitis (6%), HIV infection (6%)
and chronic obstructive pulmonary disease (2%).
The most frequently coded HZ diagnosis was ICD-9
-CM 053.9 (HZ without complications) (Table 4). A total
of 679 patients admitted to hospital with HZ as first
listed diagnosis were not coded as a HZ case in SIA.
Chart review of 50 of these patients showed the reasons
for not coding to be death, change of address, lack of
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follow-up, or no HZ ICD-9-CM codification but men-
tioning hospitalization under other ICD-9-CM code.
Figure 2 depicts the age incidence in this study and in
the prospective study [35]. In both studies the annual
incidence was higher in females. The prospective study
showed an incidence of 4.5/1000 PY (95% CI: 3.5-5.4) in
females and 2.7/1000 PY (95% CI: 1.9-3.5) in males,
while the electronic database showed an incidence of
5.32 (5.26-5.37) per 1000 PY for women and 3.86
(3.82-3.90) per 1000 PY for men (Table 1).
Discussion
In this study we used medical electronic databases from
a region of Spain in order to reliably estimate HZ inci-
dence. Our results showed an HZ incidence of 4.60/1000
PY, with a strong correlation to age, and with a drop in
incidence in patients ≥ 80 years of age, which was not ob-
served in hospitalizations. Incidence rates were higher
among women in most age groups, with an overall figure
of 3.86 in males and 5.32 PER 1000 PY in females.
Epidemiological studies on HZ in Spain are scarce and
are needed for future estimations of disease burden
[35,36,42,43]. Our study used health databases that cover
almost the entire population living in the Valencian
Community, including hospitalizations and ambulatory
patients. To the best of our knowledge, there is only one
study of similar characteristics in Spain, conducted in
Navarra (a northern region of the country) before sys-
tematic varicella vaccination [44].
One of the limitations of the study is that the Abucasis
database was not developed for medical billing purposes,
and this may imply the obtainment of less detailed infor-
mation. Although ICD-9-CM codes are routinely used,
general practitioners (GP) may be unaware of its import-
ance. To overcome this, codification is performed in
simple way – the system presenting a list of possible
ICD-9-CM codes after the diagnosis is written. In the
case of Zoster, which is a common diagnosis, with no
synonyms, ICD-9 coding is relatively easy. On the other
hand, trained personnel codify CMBD. In order to assess
the reliability of HZ codification, a random review of
medical records showed good matching between ICD-9-
CM coding and a real episode of HZ. A total of 7.7% of
the reviewed notes with the diagnosis of Herpes Zoster
did not meet the full requirements for being considered
a case. Most of these situations were due to a lack of de-
scription of the lesions. We considered that most of
these cases could be HZ, but the GP did not provide suf-
ficient written details, possibly because of the great care
burden found in primary care, which prevents entering
detailed information in medical notes. This consequently
may have understated HZ case confirmation.
For recurrent cases our temporal filters were not
wholly suitable, and therefore the system did not allow
for analysis of recurrent cases.
Another limitation is that emergency room visits and
private medical visits were not included in any of the da-
tabases. Since the medication usually prescribed for HZ
is expensive and is not subsidized in these situations, we
assumed that only a minority of patients would not seek
public medical care in order to receive subsidized drugs.
As a population database study, it is possible that some
individuals did not seek medical care. Another limitation
to be taken into account is that we only included clinical
diagnoses of HZ, since laboratory confirmation of HZ is
rarely used in normal clinical practice.
Due to bureaucratic problems, SIA data for the year
2010 were given until 20 December. We assume that the
remaining 11 days would have no significant impact
upon our estimations.
On comparing results corresponding to 2007 from the
Abucasis database and a prospective study carried out in
Figure 1 Incidence of HZ / 1000 person-years by age-groups, Valencian Community, Spain,years 2007-2010.
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Table 1 Annual incidence rate (2007-2010) for HZ per 1000 PY (adjusted population*) per age-group in the Valencian Community (Spain)

























0–14 1324 (561405) 2.36 (2.23–2.49) 1638 (690421) 2.37 (2.26–2.49) 1715 (762629) 2.25(2.14–2.36) 1610 (800131) 2.01(1.91–2.11) 2,12 (2.04–2.19) 2.36 (2.27–2.44)
15–29 1702 (727512) 2.34 (2.23–2.45) 2246 (859724) 2.61 (2.50–2.72) 2219 (912691) 2.43(2.33–2.53) 2077 (914068) 2.27(2.17–2.37) 2,26 (2.19–2.34) 2,57 (2.49–2.65)
30–39 1548 (663307) 2.33 (2.22–2.45) 2051 (804937) 2.55 (2.44–2.66) 2271 (890097) 2.55 (2.45–2.66) 2156 (923521) 2.33 (2.24–2.4) 2,19 (2.12–2.26) 2.72 (2.64–2.80)
40–49 1796 (558784) 3.21 (3.07–3.36) 2401 (685727) 3.50 (3.36–3.64) 2460 (761831) 3.23 (3.10–3.36) 2299 (804414) 2.86 (2.74–2.97) 2,68 (2.59–2.76) 3,72 (3.62–3.82)
50–59 2782 (426382) 6.52 (6.28–6.77) 3586 (521416) 6.88 (6.65–7.10) 3732 (579549) 6.44 (6.23–6.65) 3630 (621615) 5.84 (5.65–6.03) 4,85 (4.72–4.99) 7,87 (7.70–8.04)
60–69 3200 (359492) 8.90 (8.59–9.21) 4145 (435089) 9.53 (9.24–9.82) 4534 (489996) 9.25 (8.99–9.52) 4414 (514783) 8.57 (8.32–8.83) 7.73 (7.54–7.91) 10.26 (10.05–10.46)
70–79 3235 (304607) 10.62 (10.26–10.98) 4026 (359151) 11.21 (10,87–11.55) 4188 (385600) 10.86 (10.53–11.19) 3939 (403616) 9.76 (9.46–10.06) 9.41 (9.18–9.65) 11.55 (11.32–11.79)
≥ 80 1718 (179060) 9.59 (9.14–10.05) 2265 (215358) 10.52 (10.09–10.95) 2331 (242269) 9.62 (9.23–10.01) 2348 (250391) 9.38 (9.00–9.75) 9.55 (9.21–9.89) 9.88 (9.27–10.14)
Total 17305 (3780550) 4.58 (4.51–4.65) 22358 (4571822) 4.89 (4.83–4.95) 23450 (5024661) 4.67 (4.61–4.73) 22473 (5232539) 4.29 (4.24–4.35) 3.86 (3.82–3.90) 5.32 (5.26–5.37)





















a similar population (>14 years) [35,36], the incidence
figures were found to be similar, being slightly higher
when using the electronic database (5.0/1000 PY versus
4.1/1000 PY). These differences mainly occurred in two
age groups (15-49 and 60-69 years), and as the authors
point out [35], this may reflect their low precision. The
study conducted in Navarra [42] showed a mean HZ in-
cidence of 4.25/1000 PY during 2005-2006.
The number of hospitalizations in our study was lower
than in similar retrospective Spanish studies during the
previous study period [41,42]. In one of these studies
[41], differences were found among the Spanish autono-
mous communities, with lower incidence rates in the
Valencian Community. To confirm the reliability of our
data, we compared them with the national data for the
same study period (data not shown), and found both
figures to be the same, with a decrease in the incidence
of HZ hospitalization over time, possibly due to changes
in admission criteria, to greater awareness among physi-
cians of the need for early antiviral treatment, or to
changes in coding practices. However, similar hospitali-
zations rates were found (2.69/100,000 PY) in another
Spanish study using the CMBD database for the study
period 1997-2004 [45].
As in other epidemiological studies, the incidence of HZ
is strongly sex- and age-related, with higher incidences in
women over 50 years. Our incidence was slightly higher
than in other European studies using electronic databases.
In France, the yearly HZ incidence rate for all ages aver-
aged 3.82/1000 PY in the study period 2005-2008 [46],
while in Italy a retrospective study showed an incidence of
4.31/1000 PY for population aged 15 years or older during
the three-year study period (2003-2005) [47]. Another
study conducted in the Netherlands during 1994-1999,
calculated an HZ incidence of 3.4/1000 PY [48]. A similar
German study performed in an older population (≥ 50
years) reported higher figures (9.60/1000 PY during 2007-
2008) [49]. We found similar rates in the United States:
4.4/1000 PY for all ages during 2006 [50]. Apart from the
fact that the results of different descriptive epidemiological
Table 2 Hospitalizations due to Herpes Zoster by age-groups in the Valencian Community (Spain), 2007-2010
Age group (years) Population Cases Incidence * 95% CI Total HZ cases in the population Hospitalization rates**
0–14 3,142,807 40 1.27 0.88 – 1.67 6287 6.36
15–29 3,831,527 22 0.57 0.33 – 0.81 8244 2.67
30–39 3,667,802 47 1.28 0.92 – 1.65 8026 5.86
40–49 3,137,382 49 1.56 1.12 – 2.00 8956 5.47
50–59 2,397,883 52 2.17 1.58 – 2.76 13730 3.79
60–69 2,008,718 91 4.53 3.60 – 5.46 16293 5.60
70–79 1,627,844 156 9.58 8.08 – 11.09 15388 10.14
80+ 991,106 156 15.74 13.27 – 18.21 8662 18.01
Total 20,805,069 613 2.95 2.71 – 3.18 85586 7.16
*Cases per 100,000 person-years.
**Hospitalization rates (number of hospitalizations per 1000 cases of HZ).
Table 3 Characteristics of hospitalizations due to Herpes Zoster in the Valencian Community (Spain) 2007-2010
Hospital admissions 2007 2008 2009 2010 Total
Discharges with 1st-9th listed HZ related ICD-9-CM code
Number of admissions 325 395 334 401 1458
Median age (years) (min-max) 66.67 (1–95) 67.64 (0–97) 66.47 (0–100) 68.94 (1–99) 67.51 (0–100)
Men/Women 155/173 172/223 152/182 201/200 680/778
Sex ratio (M/W) 0.89 0.77 0.83 1.01 0.87
Average length of stay (days) (SD) 10.56 (11.43) 10.12 (12.01) 9.82 (10.63) 8.65 (8.29) 9.75 (10.67)
Discharges with 1st-2nd listed HZ related ICD-9-CM code
Number of admissions 135 153 136 189 613
Median age (years) (min-max) 60.19 (1–95) 62.49 (0–93) 60.19 (0–97) 65.50 (1–97) 62.44 (0–97)
Men/Women 61/74 73/80 63/73 98/91 295/318
Sex ratio (M/W) 0.82 0.91 0.86 1.08 0.93
Average length of stay (days) (SD) 7.73 (6.78) 7.98 (7.69) 7.15 (5.93) 7.47 (5.96) 7.59 (6.61)
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studies are highly dependent upon the methodology used,
some of these studies included emergency room visits,
and some countries use ICD-9-CM for billing purposes,
which would result in variable incidence rates.
Higher incidence rates were found in the placebo con-
trols of clinical trials in the ≥ 60 years age group, specif-
ically 13.00/1000 PY [50,51] or 11.12/1000 PY [28],
which indicates that an active search of HZ cases con-
siderably increases their incidence.
Our incidence peaked at 70-79 years of age and de-
creased thereafter, especially in the ≥95 years age group
(data not shown). This drop in incidence was not seen
in hospitalizations (Table 3). There are several explana-
tions for this. Firstly, there could be a gradually reduced
risk of HZ, explained by the hypothesis that exposure to
VZV provides the host with progressive immunity to
VZV reactivation [52,53]. Secondly, large proportions of
subjects in this age group have disabilities or walking
difficulties, and consequently are usually visited by
family physicians at home. These visits are commonly
not recorded in the Abucasis database, and medical pre-
scriptions are handwritten. On the other hand, many of
these patients live with relatives and usually move to
other provinces outside our study area during part of
the year, without unsubscribing from the Abucasis data-
base; a potential HZ case therefore could have been
registered elsewhere and not be counted as an incident
case.
HZ incidence is age-related. This correlation could
be explained by the progressive decline in VZV cell-
Table 4 Number of Herpes Zoster - related medical encounters (visits) and proportion of HZ diagnoses (ICD-9-CM
codes), 2007-2010
ICD-9-CM codes (Description) Number of medical visits (proportion %)
Hospital admissions Outpatient*
ICD-9-CM1st-9th ICD-9-CM1st-2nd
053.9 (Herpes zoster without complications) 812 (55.50) 328 (53.52) 70816 (36.93)
0.53.19 (Herpes zoster with other nervous system complications) 330 (22.63 94 (14.85) 3326 (1.73)
053.79 (Herpes zoster with other specified complications) 61 (4.17) 46 (7.27) 532 (0.28)
053.20 (Herpes zoster with ophthalmic complications) 51 (3.49) 28 (4.42) 7313 (0.38)
053.29 (Herpes zoster with other ophthalmic complications) 50 (3.42) 28 (4.42) 312 (0.16)
053.12 (Postherpetic trigeminal neuralgia) 45 (3.08) 20 (3.16) 4729 (2.47)
053.13 (Postherpetic polyneuropathy) 32 (2.19) 10 (1.58) 1821 (0.95)
053.11 (Geniculate herpes zoster) 29 (1.98) 19 (3.02) 496 (0.26)
053.8 (Herpes zoster with unspecified complications) 27 (1.85) 21 (3.43) 663 (0.35)
053 (Herpes Zoster without specification) 0 0 94950 (49.52)
Other 56 (3.82) 39 (6.16) 6778 (3.54)
Total (medical visits under HZ ICD-9-CM codes / number of patients) 1463/1458 633/613 191736 (85586)
Outpatient: * includes HZ ICD-9-CM codifications (053.0-053.9) for all medical visits.
Figure 2 Description of the incidence of HZ per 1000 person-year by age (95% CI) in this study and in a prospective study in Valencia [35].
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mediated immunity related to aging. The incidence
should increase in a progressively aging population,
which would imply a greater burden and cost of disease.
Determinants of direct costs of an HZ episode are usu-
ally related to the prescription of antiviral drugs and re-
petitive primary care visits in the case of PHN. Direct
outpatient costs in several European countries average
between 72.05 € and 247 € [36,54-56].
Conclusions
Our study confirms electronic databases as a reliable
epidemiological tool for estimating the incidence of HZ
disease. They provide an important source of informa-
tion on the incidence of HZ, which can be useful to
define trends in disease burden before and after HZ vac-
cine introduction.
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